Suven Life Sciences · NSE: SUVEN · BSE: 530239
Q4 FY22 results · Jan–Mar 2022
Suven Life Sciences reported revenue from operations of ₹4.22 crore (up 171.1% from Q4 FY21) and net loss of ₹20.80 crore for Q4 FY22 (Jan–Mar 2022), on a consolidated basis.
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 4.22 | 1.56 | +171.1% | 4.43 | −4.8% |
| Other income | 0.12 | 1.32 | −91.1% | 0.14 | −16.1% |
| Total income | 4.34 | 2.88 | +50.7% | 4.57 | −5.1% |
| Profit before tax | (20.80) | (21.57) | Loss narrowed | (33.69) | Loss narrowed |
| Net profit for the period | (20.80) | (21.61) | Loss narrowed | (33.69) | Loss narrowed |
| EPS, basic (₹) | (1.63) | (1.70) | not comparable | (2.65) | not comparable |
| Net margin (%) | -492.7 | -1388.0 | -760.0 |
| Item | Q4 FY22 | Q4 FY21 | YoY | Q3 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 4.22 | 1.56 | +171.1% | 4.43 | −4.8% |
| Other income | 0.12 | 1.32 | −91.1% | 0.14 | −16.2% |
| Total income | 4.34 | 2.88 | +50.7% | 4.57 | −5.1% |
| Profit before tax | (8.55) | (8.46) | Loss widened | (8.22) | Loss widened |
| Net profit for the period | (8.55) | (8.51) | Loss widened | (8.22) | Loss widened |
| EPS, basic (₹) | (0.67) | (0.67) | not comparable | (0.65) | not comparable |
| Net margin (%) | -202.6 | -546.4 | -185.4 |
Consolidated
- Filed with BSE
- 12 May 2022, 15:29 IST
- Board meeting
- 07 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 12 May 2022, 15:29 IST
- Board meeting
- 07 May 2022
- Period
- 01 Jan 2022 to 31 Mar 2022
- Review status
- Audited
- Source
- XBRL filing on BSE